CA2324988A1 - Methods for treatment and prevention of infections - Google Patents

Methods for treatment and prevention of infections Download PDF

Info

Publication number
CA2324988A1
CA2324988A1 CA002324988A CA2324988A CA2324988A1 CA 2324988 A1 CA2324988 A1 CA 2324988A1 CA 002324988 A CA002324988 A CA 002324988A CA 2324988 A CA2324988 A CA 2324988A CA 2324988 A1 CA2324988 A1 CA 2324988A1
Authority
CA
Canada
Prior art keywords
seq
group
tyr
infection
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002324988A
Other languages
English (en)
French (fr)
Inventor
Kathleen E. Rodgers
Gere Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2324988A1 publication Critical patent/CA2324988A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/32—Angiotensins [AT], angiotensinogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002324988A 1998-04-09 1999-04-07 Methods for treatment and prevention of infections Abandoned CA2324988A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8126298P 1998-04-09 1998-04-09
US60/081,262 1998-04-09
US8902498P 1998-06-12 1998-06-12
US60/089,024 1998-06-12
PCT/US1999/007654 WO1999052540A1 (en) 1998-04-09 1999-04-07 Methods for treatment and prevention of infections

Publications (1)

Publication Number Publication Date
CA2324988A1 true CA2324988A1 (en) 1999-10-21

Family

ID=26765405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002324988A Abandoned CA2324988A1 (en) 1998-04-09 1999-04-07 Methods for treatment and prevention of infections

Country Status (5)

Country Link
EP (1) EP1067952A1 (ja)
JP (1) JP2002511416A (ja)
AU (1) AU752041B2 (ja)
CA (1) CA2324988A1 (ja)
WO (1) WO1999052540A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
CA2449150C (en) 2001-05-31 2011-07-12 Vicore Pharma Ab Tricyclic compounds useful as angiotensin ii agonists
CA2448051A1 (en) * 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
WO2002098448A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
US20090227507A1 (en) * 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
EP2603228A1 (en) * 2010-08-10 2013-06-19 The University Of Southern California Use of angiotensin- ii (1-7) in cell transplantation and as an agent for preventing/treating norovirus infection
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair
DE69429450T2 (de) * 1993-09-24 2002-07-25 University Of Southern California, Los Angeles Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung

Also Published As

Publication number Publication date
JP2002511416A (ja) 2002-04-16
EP1067952A1 (en) 2001-01-17
AU3479099A (en) 1999-11-01
AU752041B2 (en) 2002-09-05
WO1999052540A1 (en) 1999-10-21

Similar Documents

Publication Publication Date Title
AU759285B2 (en) Methods to increase white blood cell survival after chemotherapy
EP1275396B1 (en) Use of angiotensin II fragments and analogs thereof in tissue repair
EP1333034B1 (en) Use of angiotensin II analogs in tissue repair
US7786085B2 (en) Method for treating a patient undergoing chemotherapy
US7118748B1 (en) Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
AU706333B2 (en) Use of angiotensin III and analogs thereof in tissue repair
ES2377931T5 (es) Métodos para preparar lipopéptidos purificados
WO1996014858A9 (en) Use of angiotensin ii fragments and analogs thereof in tissue repair
US6762167B1 (en) Methods for treating a patient undergoing chemotherapy
AU752041B2 (en) Methods for treatment and prevention of infections
US20050004036A1 (en) Methods for treating and preventing damage to mucosal tissue
ES2267513T3 (es) Angiotensina ii y analogos de la misma para limitar la formacion de cicatrices y de adherencias.
JP4817335B2 (ja) 新規抗菌性ペプチド
AU2021200731B2 (en) Pro-drug peptide with improved pharmaceutical properties
EP1239867B1 (en) Methods for treating and preventing damage to mucosal tissue
WO2001055176A2 (en) Methods for inhibiting smooth muscle cell proliferation
MXPA00009896A (en) Methods for treatment and prevention of infections
MXPA00011112A (en) Methods to increase white blood cell survival after chemotherapy
Śleszyńska et al. receptor antagonists—influence of C-terminal segment modifications on their pharmacological properties

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead